This company has been marked as potentially delisted and may not be actively trading. Vaccitech (VACC) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsInsider TradesTrendsBuy This Stock VACC vs. BIOA, NLTX, CYBN, VIRI, LITS, WHWK, OSTX, ELYM, ATNM, and AADIShould you be buying Vaccitech stock or one of its competitors? The main competitors of Vaccitech include BioAge Labs (BIOA), Neoleukin Therapeutics (NLTX), Cybin (CYBN), Virios Therapeutics (VIRI), Lite Strategy (LITS), Whitehawk Therapeutics (WHWK), OS Therapies (OSTX), Eliem Therapeutics (ELYM), Actinium Pharmaceuticals (ATNM), and Aadi Bioscience (AADI). Vaccitech vs. Its Competitors BioAge Labs Neoleukin Therapeutics Cybin Virios Therapeutics Lite Strategy Whitehawk Therapeutics OS Therapies Eliem Therapeutics Actinium Pharmaceuticals Aadi Bioscience BioAge Labs (NASDAQ:BIOA) and Vaccitech (NASDAQ:VACC) are both small-cap pharmaceutical preparations industry companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, media sentiment, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends. Does the media favor BIOA or VACC? In the previous week, BioAge Labs had 3 more articles in the media than Vaccitech. MarketBeat recorded 3 mentions for BioAge Labs and 0 mentions for Vaccitech. BioAge Labs' average media sentiment score of 0.83 beat Vaccitech's score of 0.00 indicating that BioAge Labs is being referred to more favorably in the media. Company Overall Sentiment BioAge Labs Positive Vaccitech Neutral Do analysts rate BIOA or VACC? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioAge Labs 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Vaccitech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is BIOA or VACC more profitable? BioAge Labs has a net margin of 0.00% compared to Vaccitech's net margin of -409.18%. Vaccitech's return on equity of -23.41% beat BioAge Labs' return on equity.Company Net Margins Return on Equity Return on Assets BioAge LabsN/A -25.39% -23.22% Vaccitech -409.18%-23.41%-20.85% Which has stronger earnings & valuation, BIOA or VACC? Vaccitech has higher revenue and earnings than BioAge Labs. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioAge Labs$3.86M50.23-$71.11MN/AN/AVaccitech$13.42M4.19$5.34M-$1.43-1.02 Do institutionals and insiders believe in BIOA or VACC? 26.1% of Vaccitech shares are held by institutional investors. 20.8% of BioAge Labs shares are held by insiders. Comparatively, 6.0% of Vaccitech shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. SummaryBioAge Labs beats Vaccitech on 6 of the 11 factors compared between the two stocks. Get Vaccitech News Delivered to You Automatically Sign up to receive the latest news and ratings for VACC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VACC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VACC vs. The Competition Export to ExcelMetricVaccitechPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$56.28M$983.40M$6.12B$10.64BDividend YieldN/A4.84%5.66%4.69%P/E Ratio-1.021.2886.1127.75Price / Sales4.1931.01588.17183.92Price / Cash19.3017.6438.3262.20Price / Book0.227.3812.976.80Net Income$5.34M-$7.96M$3.30B$275.97M Vaccitech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VACCVaccitechN/A$1.46-3.3%N/A+24.8%$56.28M$13.42M-1.0233Gap DownBIOABioAge Labs0.1742 of 5 stars$5.90-0.3%N/AN/A$211.52MN/A0.00N/ANews CoveragePositive NewsAnalyst ForecastNLTXNeoleukin TherapeuticsN/A$17.98+3.7%N/A-52.6%$168.93MN/A-5.7890High Trading VolumeCYBNCybinN/A$6.21+3.8%$85.00+1,268.8%N/A$156.42MN/A-1.4250High Trading VolumeVIRIVirios TherapeuticsN/A$7.07-8.2%$5.00-29.3%+125.4%$136.15MN/A-26.195Gap UpLITSLite StrategyN/A$2.68+4.7%N/AN/A$95.54M$65.30M-0.56100News CoverageAnalyst ForecastGap UpWHWKWhitehawk Therapeutics0.6724 of 5 stars$1.94+1.6%N/AN/A$91.43M$25.98M-32.3321News CoverageAnalyst UpgradeOSTXOS TherapiesN/A$1.99-0.5%$18.00+804.5%N/A$62.97MN/A-2.52N/AGap UpELYMEliem TherapeuticsN/A$1.97-2.0%N/A-65.6%$58.61MN/A-3.729ATNMActinium Pharmaceuticals1.9113 of 5 stars$1.60flat$4.50+181.3%-4.2%$49.91MN/A-1.1530AADIAadi BioscienceN/A$1.91+0.5%N/A+7.0%$47.17M$25.07M-0.8440 Related Companies and Tools Related Companies BioAge Labs Competitors Neoleukin Therapeutics Competitors Cybin Competitors Virios Therapeutics Competitors Lite Strategy Competitors Whitehawk Therapeutics Competitors OS Therapies Competitors Eliem Therapeutics Competitors Actinium Pharmaceuticals Competitors Aadi Bioscience Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VACC) was last updated on 10/10/2025 by MarketBeat.com Staff From Our PartnersBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredTrump to get REVENGE on the banks??Rumors are swirling that Trump could target the banking system by upending the $5 trillion-a-day SWIFT network...The Oxford Club | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaccitech plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaccitech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
